dorzagliatin + empagliflozin

dorzagliatin + empagliflozin is an investigational oral combination therapy targeting type 2 diabetes mellitus (T2DM). Dorzagliatin is a dual-acting, orally bioavailable, allosteric activator of glucokinase, enhancing both pancreatic and hepatic glucose sensing, stimulating insulin and GLP-1 secretion, and improving β-cell function and hepatic insulin sensitivity. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that acts in the proximal renal tubule to block glucose reabsorption and increase urinary glucose excretion, reducing blood glucose. The combination aims to provide synergistic glycemic control without significant pharmacokinetic interaction. Preclinical and early clinical evidence suggests the combination preserved the mechanisms of both drugs and may offer additive or synergistic benefits over monotherapy, with potential additional effects on glucagon secretion and cardiovascular outcomes[1][3][7].